Post-traumatic Stress Disorder (PTSD) Treatment Market Analysis

  • Report ID: 6496
  • Published Date: Sep 18, 2025
  • Report Format: PDF, PPT

Post-traumatic Stress Disorder Treatment Market Segmentation:

Demographics Segment Analysis

In post-traumatic stress disorder (PTSD) treatment market, adult segment is expected to account for more than 84.7% revenue share by the end of 2035. Adults, especially those exposed to trauma, represent a substantial portion of PTSD cases, driving demand for effective treatments.  The prevalence of PTSD among adults is considered to be on the higher side. According to the American Psychiatric Association, about 3.5% of adults in the U.S. experience PTSD each year. Teenagers between the ages of 13 and 18 have an 8% lifetime frequency of PTSD. One in every eleven people is predicted to have a PTSD diagnosis at some point in their lives. PTSD affects women twice as frequently as men.

Moreover, as awareness of mental health issues rises, adults are more likely to seek treatment, breaking down barriers and reducing stigma. Also, the popularity of telehealth has made accessing PTSD treatment more convenient for adults, further driving PTSD treatment market growth.

Drug Class Segment Analysis

Antidepressants segment is anticipated to dominate post-traumatic stress disorder treatment market share of around 48.2% by the end of 2035. SSRIs (selective serotonin reuptake inhibitors) such as sertraline-containing Zoloft and paroxetine-containing Paxil are often prescribed for PTSD, demonstrating effectiveness in reducing symptoms, which increases their use. Antidepressants can help with symptoms such as depression, anxiety, and sleep difficulties. They function by controlling the brain's levels of specific neurotransmitters, such as norepinephrine and serotonin, which can be out of balance in PTSD sufferers.

Distribution Channel Segment Analysis

By the end of 2035, retail pharmacy segment is anticipated to capture post-traumatic stress disorder treatment market share of around 63.6%. Treatment for post-traumatic stress disorder requires both short- and long-term pharmacological assistance, which promotes the expansion of retail pharmacies. Furthermore, retail pharmacists are comfortable dispensing major drugs, particularly in-home care settings.  Additionally, retail pharmacies often engage in health promotion activities about, raising awareness about PTSD and available treatments, which can lead to more patients seeking help.

Our in-depth analysis of the post-traumatic stress disorder (PTSD) treatment market includes the following segments

          Demographics

  • Adult
  • Children

          Drug Class

  • Antidepressants
  • Antipsychotics
  • Anti-anxiety

          Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of post-traumatic stress disorder treatment is assessed at USD 2.14 billion.

The global post-traumatic stress disorder treatment market size surpassed USD 2.04 billion in 2025 and is projected to grow at a CAGR of over 5.7%, reaching USD 3.55 billion revenue by 2035.

North America post-traumatic stress disorder (PTSD) treatment market will account for 40.70% share by 2035, attributed to high PTSD prevalence and demand for mental health care.

Key players in the market include Jazz Pharmaceuticals plc, Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc (GSK plc), Viatris Inc., Jubilant Pharmova Ltd., H. Lundbeck A/S, Camber Pharmaceuticals, Inc..
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos